全文获取类型
收费全文 | 1407618篇 |
免费 | 115708篇 |
国内免费 | 3329篇 |
专业分类
耳鼻咽喉 | 18354篇 |
儿科学 | 46549篇 |
妇产科学 | 41048篇 |
基础医学 | 200704篇 |
口腔科学 | 37680篇 |
临床医学 | 125885篇 |
内科学 | 284061篇 |
皮肤病学 | 33349篇 |
神经病学 | 116796篇 |
特种医学 | 53823篇 |
外国民族医学 | 464篇 |
外科学 | 210468篇 |
综合类 | 32747篇 |
现状与发展 | 3篇 |
一般理论 | 487篇 |
预防医学 | 109865篇 |
眼科学 | 31478篇 |
药学 | 98490篇 |
1篇 | |
中国医学 | 3347篇 |
肿瘤学 | 81056篇 |
出版年
2021年 | 10845篇 |
2019年 | 11659篇 |
2018年 | 16565篇 |
2017年 | 12666篇 |
2016年 | 14261篇 |
2015年 | 16003篇 |
2014年 | 22555篇 |
2013年 | 33391篇 |
2012年 | 45380篇 |
2011年 | 47916篇 |
2010年 | 28153篇 |
2009年 | 27046篇 |
2008年 | 44316篇 |
2007年 | 46825篇 |
2006年 | 47380篇 |
2005年 | 45854篇 |
2004年 | 43743篇 |
2003年 | 41689篇 |
2002年 | 40180篇 |
2001年 | 72998篇 |
2000年 | 74528篇 |
1999年 | 61556篇 |
1998年 | 16989篇 |
1997年 | 15429篇 |
1996年 | 15584篇 |
1995年 | 14788篇 |
1994年 | 13394篇 |
1993年 | 12581篇 |
1992年 | 45835篇 |
1991年 | 43476篇 |
1990年 | 41490篇 |
1989年 | 39552篇 |
1988年 | 36182篇 |
1987年 | 35355篇 |
1986年 | 32867篇 |
1985年 | 31279篇 |
1984年 | 23826篇 |
1983年 | 20024篇 |
1982年 | 12208篇 |
1981年 | 10780篇 |
1979年 | 20702篇 |
1978年 | 14578篇 |
1977年 | 12085篇 |
1976年 | 11367篇 |
1975年 | 11622篇 |
1974年 | 13993篇 |
1973年 | 13534篇 |
1972年 | 12634篇 |
1971年 | 11469篇 |
1970年 | 10910篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
141.
O. Morris M. Fairclough J. Grigg C. Prenant A. McMahon 《Journal of labelled compounds & radiopharmaceuticals》2019,62(1):4-23
Affinity peptide and protein‐ (APP) based radiotracers are an increasingly popular class of radiotracer in positron emission tomography (PET), which was once dominated by the use of small molecule radiotracers. Radiolabelled monoclonal antibodies (mAbs) are important examples of APPs, yet a preference for smaller APPs, which exhibit fast pharmacokinetics and permit rapid PET aided diagnosis, has become apparent. 18F exhibits favourable physical characteristics for APP radiolabelling and has been described as an ideal PET radionuclide. Notwithstanding, 18F radiolabelling of APP is challenging, and this is echoed in the literature where a number of diverse approaches have been adopted. This review seeks to assess and compare the approaches taken to 18F APP radiolabelling with the intention of highlighting trends within this expanding field. Generic themes have emerged in the literature, namely the use of mild radiolabelling conditions, a preference of site‐specific methodologies with an impetus for short, automated procedures which produce high‐yielding [18F]APPs. 相似文献
142.
143.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献144.
145.
146.
147.
148.
Shylo R. Johnson Dennis Slate Kathleen M. Nelson Amy J. Davis Samual A. Mills John T. Forbes Kurt C. VerCauteren Amy T. Gilbert Richard B. Chipman 《Viruses》2021,13(2)
Since the 1990s, oral rabies vaccination (ORV) has been used successfully to halt the westward spread of the raccoon rabies virus (RV) variant from the eastern continental USA. Elimination of raccoon RV from the eastern USA has proven challenging across targeted raccoon (Procyon lotor) and striped skunk (Mephitis mephitis) populations impacted by raccoon RV. Field trial evaluations of the Ontario Rabies Vaccine Bait (ONRAB) were initiated to expand ORV products available to meet the rabies management goal of raccoon RV elimination. This study describes the continuation of a 2011 trial in West Virginia. Our objective was to evaluate raccoon and skunk response to ORV occurring in West Virginia for an additional two years (2012–2013) at 75 baits/km2 followed by three years (2014–2016) of evaluation at 300 baits/km2. We measured the change in rabies virus-neutralizing antibody (RVNA) seroprevalence in targeted wildlife populations by comparing levels pre- and post-ORV during each year of study. The increase in bait density from 75/km2 to 300/km2 corresponded to an increase in average post-ORV seroprevalence for raccoon and skunk populations. Raccoon population RVNA levels increased from 53% (300/565, 95% CI: 50–57%) to 82.0% (596/727, 95% CI: 79–85%) during this study, and skunk population RVNA levels increased from 11% (8/72, 95% CI: 6–20%) to 39% (51/130, 95% CI: 31–48%). The RVNA seroprevalence pre-ORV demonstrated an increasing trend across study years for both bait densities and species, indicating that multiple years of ORV may be necessary to achieve and maintain RVNA seroprevalence in target wildlife populations for the control and elimination of raccoon RV in the eastern USA. 相似文献
149.
150.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687